209 related articles for article (PubMed ID: 38280846)
1. iPSC-derived models of PACS1 syndrome reveal transcriptional and functional deficits in neuron activity.
Rylaarsdam L; Rakotomamonjy J; Pope E; Guemez-Gamboa A
Nat Commun; 2024 Jan; 15(1):827. PubMed ID: 38280846
[TBL] [Abstract][Full Text] [Related]
2. Neural deficits in a mouse model of PACS1 syndrome are corrected with PACS1- or HDAC6-targeting therapy.
Villar-Pazos S; Thomas L; Yang Y; Chen K; Lyles JB; Deitch BJ; Ochaba J; Ling K; Powers B; Gingras S; Kordasiewicz HB; Grubisha MJ; Huang YH; Thomas G
Nat Commun; 2023 Oct; 14(1):6547. PubMed ID: 37848409
[TBL] [Abstract][Full Text] [Related]
3. RNA-targeted therapy corrects neuronal deficits in PACS1 syndrome mice.
Villar-Pazos S; Thomas L; Yang Y; Chen K; Lyles JB; Deitch BJ; Ochaba J; Ling K; Powers B; Gingras S; Kordasiewicz HB; Grubisha MJ; Huang YH; Thomas G
Res Sq; 2023 Jan; ():. PubMed ID: 36747781
[TBL] [Abstract][Full Text] [Related]
4. Genetic characterization of Schuurs-Hoeijmakers syndrome in a moroccan individual with heterozygote PACS1 mutation.
Abbassi M; Bourmtane A; Sayel H; El Mouhi H; Jalte M; Elasri YA; Askander O; El Fahime E; Bouguenouch L
Mol Biol Rep; 2023 Nov; 50(11):9121-9128. PubMed ID: 37747683
[TBL] [
